Metabolomics: a novel approach to identify potential diagnostic biomarkers and pathogenesis in Alzheimer's disease.
Neurosci Bull
; 28(5): 641-8, 2012 Oct.
Article
em En
| MEDLINE
| ID: mdl-23054640
ABSTRACT
Although the pathogenesis of Alzheimer's disease (AD) is still not fully understood, it is acknowledged that intervention should be made at the early stage. Therefore, identifying biomarkers for the clinical diagnosis is critical. Metabolomics, a novel "omics", uses methods based on low-molecular-weight molecules, with high-throughput evaluation of a large number of metabolites that may lead to the identification of new disease-specific biomarkers and the elucidation of pathophysiological mechanisms. This review discusses metabolomics investigations of AD and potential future developments in this field.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Metabolômica
/
Doença de Alzheimer
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
/
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Neurosci Bull
Ano de publicação:
2012
Tipo de documento:
Article